LS Newman, C Bobka, B Schumacher, E Daniloff, B Zhen, MM Mroz and TE King Jr
Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado.

Although beryllium disease has been associated with a bronchoalveolar lavage (BAL) lymphocytosis and T cell-mediated immune response, we do not know if either the BAL cellular profile or the compartmentalized pulmonary response to the antigen reflect the severity of the disease. We studied 110 subjects divided into three groups of subjects: beryllium disease patients (n = 55), beryllium-sensitized patients without disease (n = 8), and control subjects (n = 47). Evaluation included completion of a respiratory symptom questionnaire, clinical examination, chest radiograph, spirometry, body plethysmographic lung volumes, and diffusing capacity (DLCO). In the patient groups, we performed maximal exercise testing with an indwelling arterial line. In addition, we examined BAL and performed blood and BAL beryllium lymphocyte transformation tests (BeLT) as measures of the beryllium- specific T cell-mediated response in these two compartments. In beryllium disease patients we correlated the BAL cellular constituents with clinical parameters indicative of disease severity. Beryllium disease patients exhibited elevated numbers of white cells and lymphocytes in BAL compared with both other groups; however, this lymphocytic alveolitis was significantly obscured in smokers. The BAL cellular constituents correlated with BAL BeLT but not with the blood BeLT. BAL cellular constituents also correlated with the radiographic profusion of small opacities, FEV1/FVC, DLCO, maximal achievable work load, VO2max, and measures of gas exchange at rest and at maximum exercise. We conclude that the lymphocyte-predominant pulmonary inflammatory response in beryllium disease is related to the magnitude of the localized response to antigen and that BAL cellularity, differential cell count, and BeLT reflect beryllium disease clinical severity.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				Y. K. Chou, D. M. Edwards, A. D. Weinberg, A. A. Vandenbark, B. L. Kotzin, A. P. Fontenot, and G. G. Burrows Activation Pathways Implicate Anti-HLA-DP and Anti-LFA-1 Antibodies as Lead Candidates for Intervention in Chronic Berylliosis J. Immunol., April 1, 2005; 174(7): 4316 - 4324. [Abstract] [Full Text] [PDF]

				A. Sood, W. S. Beckett, and M. R. Cullen Variable Response to Long-term Corticosteroid Therapy in Chronic Beryllium Disease Chest, December 1, 2004; 126(6): 2000 - 2007. [Abstract] [Full Text] [PDF]

				B. P. Barna, D. A. Culver, B. Yen-Lieberman, R. A. Dweik, and M. J. Thomassen Clinical Application of Beryllium Lymphocyte Proliferation Testing Clin. Vaccine Immunol., November 1, 2003; 10(6): 990 - 994. [Full Text] [PDF]

				A. P. Fontenot, L. A. Maier, S. J. Canavera, T. B. Hendry-Hofer, M. Boguniewicz, E. A. Barker, L. S. Newman, and B. L. Kotzin Beryllium Skin Patch Testing to Analyze T Cell Stimulation and Granulomatous Inflammation in the Lung J. Immunol., April 1, 2002; 168(7): 3627 - 3634. [Abstract] [Full Text] [PDF]

				L.A. Maier, R.T. Sawyer, S.S. Tinkle, L.A. Kittle, E.A. Barker, R. Balkissoon, C. Rose, and L.S. Newman IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis Eur. Respir. J., March 1, 2001; 17(3): 403 - 415. [Abstract] [Full Text] [PDF]

				A. P. Fontenot, M. Torres, W. H. Marshall, L. S. Newman, and B. L. Kotzin Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease PNAS, October 23, 2000; (2000) 220430797. [Abstract] [Full Text]

				A. P. Fontenot, M. T. Falta, B. M. Freed, L. S. Newman, and B. L. Kotzin Identification of Pathogenic T Cells in Patients with Beryllium-Induced Lung Disease J. Immunol., July 15, 1999; 163(2): 1019 - 1026. [Abstract] [Full Text] [PDF]

				L. A. MAIER, M. V. RAYNOLDS, D. A. YOUNG, E. A. BARKER, and L. S. NEWMAN Angiotensin-1 Converting Enzyme Polymorphisms in Chronic Beryllium Disease Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1342 - 1350. [Abstract] [Full Text] [PDF]

				R. J. Harbeck Clin. Vaccine Immunol., May 1, 1998; 5(3): 271 - 277. [Full Text]

				A. P. Fontenot, B. L. Kotzin, C. E. Comment, and L. S. Newman Expansions of T-cell Subsets Expressing Particular T-cell Receptor Variable Regions in Chronic Beryllium Disease Am. J. Respir. Cell Mol. Biol., April 1, 1998; 18(4): 581 - 589. [Abstract] [Full Text]

				S. Tinkle and L. Newman Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1884 - 1891. [Abstract] [Full Text]

				Y. Inoue, E. Barker, E. Daniloff, N. Kohno, K. Hiwada, and L. S. Newman Pulmonary Epithelial Cell Injury and Alveolar-Capillary Permeability in Berylliosis Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 109 - 115. [Abstract] [Full Text]

				A. P. Fontenot, M. Torres, W. H. Marshall, L. S. Newman, and B. L. Kotzin Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease PNAS, November 7, 2000; 97(23): 12717 - 12722. [Abstract] [Full Text] [PDF]